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This study sought to investigate the safety and feasibility of same day discharge 
(SDD) practice and compare clinical outcomes to patients admitted for overnight stay 
(ON) undergoing elective left main stem (LMS) percutaneous coronary intervention 
(PCI). ON observation is still widely practiced in highly complex PCI as the standard 
of care, with no previous data comparing clinical outcomes in patients undergoing 
LMS PCI. 
Methods 
We analysed 6452 patients undergoing elective LMS PCI between 2007-2014 in 
England and Wales. Multiple logistic regressions and the BCIS risk model were used 
to study association between SDD and 30-day mortality. 
Results 
SDD rates almost doubled from 19.9% in 2007 to 39.8% in 2014 for all LMS 
procedures and increased from 20.7% to 41.4% for unprotected LMS cases during the 
same study period. There was a significant increase in procedural complexity with 
higher use of rotational atherectomy, longer stents and multivessel PCI. SDD was not 
associated with increased 30-day mortality (OR 0.70 95%CI 0.30-1.65) in the overall 
LMS PCI cohort and the results were similar in unprotected LMS (OR 0.48 95%CI 
0.17-1.41) and those requiring ON stay (OR 0.58 95%CI 0.25-1.34).  
Conclusions  
We did not find evidence that SDD is not safe or feasible in highly complex LMS PCI 
procedures despite increasing procedural complexity with no significant increase in 
30-day mortality rates.  



















BCIS = British Cardiovascular Intervention Society 
CABG = Coronary Artery Bypass Graft 
MI = Myocardial Infraction 
ON = OverNight stay 
OR = Odds Ratio 
PCI = Percutaneous Coronary Intervention 














The adoption of same day discharge (SDD) following percutaneous coronary 
intervention (PCI) is increasingly common, being driven by financial pressures, a need for 
improved bed utilization, and patient preference for shorter length of stay. In reality, this 
practice varies widely amongst different healthcare systems and clinicians. Whilst clinical 
trials[1-5], observational studies[6-12] and meta-analyses[13, 14] have investigated SDD for 
its feasibility and safety compared to overnight (ON) admission, only a few single centre 
studies have examined the effectiveness of SDD practice in more complex elective cases[15-
18]. 
Treatment of unprotected left main coronary artery disease with PCI has increased 
over the last decade following the favourable results of randomised clinical trials comparing 
PCI and coronary artery bypass grafting (CABG),[19-22] and may account for up to 5% of 
contemporary PCI cases[23]. Nevertheless, PCI of unprotected left main stem (LMS) carries 
a higher risk in part because of the large amount of myocardium at risk with, and also 
because the treatment often involves the use of complex bifurcation techniques, with more 
than 80% of lesions being distal LMS bifurcations.[24] To the best of our knowledge, none of 
the prior studies that examined the safety of SDD have focused on LMS PCI cases, while 
many excluded (unprotected) LMS PCI or cited LMS PCI as one of the reasons for ON 
stay,[5, 25-30] which was in line with the 2009 guidelines from the Society for 
Cardiovascular Angiography and Interventions (SCAI)[31]. In the United Kingdom, the 
evolution of PCI practice means that many elective PCI LMS patients are now discharged on 
the same day[32] despite safety having not been previously assessed in this population. The 
most recent guidelines for LMS PCI[33] and for SDD following PCI[34] do not discuss the 
appropriateness of such practice. The last published consensus for the length of stay 
following elective PCI recommended that the decision on hospital admission or SDD should 
depend on overall patient outcome (i.e. stable Patient, successful Procedure, structured 
Program), rather than on individual procedural angiographic and procedural 
characteristics[34]. However, operators may not feel comfortable when the safety of SDD for 
more complex patients who have not been formally evaluated. 
In this study, we aimed to investigate the temporal changes in the distribution of SDD 
practice in LMS PCI and unprotected LMS PCI cases in England and Wales, as well as the 










aimed to examine which clinical and procedural characteristics were independently 
associated with SDD within the LMS PCI cases. Finally, we studied the independent 
predictors of 30-day mortality and examined the difference between the observed 30-day 
mortality rate to the expected calculated by the British Cardiovascular Intervention Society 
(BCIS) 30-day mortality risk model [35], by discharge status. 
Methods 
This retrospective study analysed data from patients that underwent elective LMS PCI 
from 1 January 2007 to 31 December 2014 in England and Wales. The BCIS collects data on 
all PCI procedures in the UK. Data input on every case is mandated by the UK Good Practice 
guidelines and is a specified responsibility of consultant operators as part of their revalidation 
by the General Medical Council. The data collection is coordinated by the National Institute 
of Cardiovascular Outcomes Research (NICOR) via a centralized electronic database. The 
BCIS-NICOR registry comprises 113 variables, including clinical variables, procedural 
parameters, and patient outcomes. The dataset’s quality has been recently described in 
detail.[36] Mortality tracking was undertaken by NHS Digital linkage to Office for National 
Statistics mortality records, using the NHS number that provides a unique identifier for any 
person registered with the NHS in England and Wales. Because it is a legal requirement for 
all deaths in the UK to be registered, these life status data are considered robust.  
Study population and variables 
Our analysis included elective cases, for patients with stable angina, aged between 18 
and 100 years old, and who underwent uncomplicated LMS PCI (PCI procedures that did not 
sustain an in-hospital complication) at an NHS centre in England and Wales. These elective 
cases are considered to be potentially eligible for SDD. Cases with missing discharge status, 
age, sex, or mortality data were excluded from the analysis. LMS PCI was defined as any PCI 
case, where the left main lesion was attempted (either on its own or with other lesions). 
Protected LMS are defined as a patient with a graft to either the left anterior descending 
artery or the left circumflex. Severity of LMS lesion prior the procedure is defined as stenosis 
>75%. Penetration catheters refer to either use of a Tornus or a Corsair catheter.  
The analysis was adjusted for information of demographics, structural cardiac and 
procedural characteristics, medication and access site (Supplementary Table 1). Additionally, 










local health services, now reorganised into NHS Regions, and calendar year were considered 
in the analysis to explore geographic differences in practice over time.  
Data analysis 
In our population, 30 variables had missing values, with the highest percentage of 
incompleteness being 37.4% for left ventricular ejection fraction (LVEF). We used multiple 
imputation by chained equations (MICE) to impute missing values, creating 10 imputed 
datasets. Studies over the performance of multiple imputation techniques have shown that 
such approaches perform well, even for variables with up to 80% missing values.[37] Each of 
the imputation models included all the other variables used in our analyses (Supplementary 
Table 1), including all considered outcomes. The imputation models were logistic regression 
for binary variables, multinomial for nominal variables, ordinal logistic regression for 
ordered factors and linear regression for continuous variables. Subsequently, the missing 
values were replaced by values drawn from the posterior distributions plus a random error 
[38, 39]. Each finalized imputed dataset was evaluated for its consistency with the original 
through summary statistics and assessment of convergence. All subsequent analyses were 
performed in each imputed dataset individually, the results of which were then pooled 
according to Rubin’s rules[40].  
Statistical analysis  
We used the unimputed data to produce graphs to display LMS prevalence over time 
(from 2007 to 2014) within the elective cohort. Similarly, we graphically displayed SDD 
change over time within the LMS. We also created spatial maps to depict temporal changes 
of SDD prevalence within the LMS cohort regionally in England and Wales. We investigated 
the temporal changes of all the variables that were included in the analysis within the SDD 
and the ON stay cohorts separately. At the same time, we fitted an appropriate regression 
model for each available variable (i.e. linear model for continuous, logistic for binary, 
multinomial logistic for nominals and ordinal logistic for ordered variables), to examine for 
differences in the distributional changes over time between the two cohorts.  
Next, using the imputed data, we fitted a multiple logistic regression model with 
indication of SDD as the outcome and with all variables of interest, plus the year of the 
procedure, as covariates to examine the variables independent associations with SDD. For 










together; Variance Inflation Factors (VIFs) were estimated to ensure there was no 
multicollinearity in the final model.  
We also observed the changes of 30-day mortality rates for the SDD and the ON stay 
cohorts separately and compared them to the expected mortality values estimated via the 
BCIS risk model [35], a well validated model published in 2016. We manually estimated the 
observed and expected mortality risks in each of the imputed datasets and pooled them to the 
mean to obtain single estimations. We fitted a multiple logistic regression to assess whether 
SDD was independently associated with observed 30-day mortality after controlling for all 
other available variables.  
Finally, as sensitivity analyses, we followed the same approach outlined above, but: a) 
focused on unprotected LMS only cases; and b) included complicated ON stay cases. 
Complication records are displayed in Supplementary Table 2; in short, these refer to patients 
that sustained any type of procedural, arterial or bleeding complications peri or post 
procedural, or presented adverse hospital outcomes.  
We used the statistical software Stata version 15 and an alpha level of 5% all through 
the data analysis. 
Results 
Following all the exclusion criteria as presented in Figure 1, our dataset included 6452 
LMS PCI cases, of which 3594 underwent unprotected LMS PCI. In total we found records 
of 339 incidences of peri- or post-procedural complications (Supplementary Table 2), while 
309 (4.6% of all elective LMS PCI) patients experienced at least one adverse episode. These 
patients were excluded from our finalised dataset and were only included within the 
sensitivity analysis. 
We observed an increase of elective LMS PCI cases over time from 2.9% in 2007 to 
5% in 2014, with unprotected LMS increasing from 2% in 2007 to 3.6% in 2014 (Figure 2). 
SDD practice has increased to a similar extent within the two groups, from 19.9% in 2007 to 
39.8% in 2014 for all the LMS cases and from 20.7% to 41.4% for unprotected LMS cases 
(Figure 3). Figure 4 and Supplementary Figure 1 display the temporal changes and the 











Table 1 shows the temporal distributional changes of each characteristic within the 
SDD and ON stay cohorts, for all the LMS cases. The prevalence of females decreased over 
time in the SDD cohorts, while increased for males. The average age was consistently lower 
in the SDD cohort but increased over time in both cohorts, from 66 years old in 2007 to 68.7 
in 2014 for the SDD group and from 67.4 to 69.8 for the ON stay cases, respectively. 
Significant medical history and comorbidity burden were consistently lower for the SDD 
cases, including hypertension, peripheral vascular disease, diabetes, renal disease, poor LVEF 
and valvular heart disease. Over the same period, there was an upward trend of SDD patients 
with valvular heart disease (from 0.9% in 2007 to 5.3% in 2014), peripheral vascular disease 
(from 2.7% to 5.0%), previous stroke (from 2.7% to 5.6%), hypertension (from 52.3% to 
66.8%) and severe pre-PCI LMS stenosis (from 30.5% to 48.1%). Further, the proportion of 
cases with poor LVEF increased from 2.4% in 2007 to 4.9% in 2014, as did diabetes from 
21% in 2007 to 28% in 2014 and renal dialysis disease from 0% to 0.7%. Similar patterns 
were observed for the unprotected LMS cases (Supplementary Table 3) and when 
complicated ON cases were included (Supplementary Table 5). 
Procedural characteristics 
Over time, we observed significant changes in the procedural characteristics for the 
overall LMS cohort, particularly in the SDD group, suggesting that SDD were increasingly 
complex. Rotational atherectomy was increasingly used over time, from 1.1% in 2007 to 
6.4% in 2014, although its use was consistently lower compared to the ON, which ranged 
from 7.6% to 13.8%, respectively. Intravascular imaging use also increased for both the SDD 
and ON stay cohorts (from 28.9% to 35.9 and from 22.6% to 37%, respectively), as did the 
use of longer stents (from 20.5 to 30.2 mm and from 22.2 to 29.3mm, respectively). 
Multivessel PCI was increasingly attempted in the SDD cases, from 38.4% in 2007 to 61.6% 
in 2014, which applies for the cases that underwent LMS PCI and one or more vessels were 
also attempted, while use of penetration catheters increased from 0% to 1.4%. Adoption of 
radial access was more frequent over time in the SDD cohort (from 24.1% to 58.3%) 
compared to the ON stay (from 17.8% to 51%). Finally, we found that increasing numbers of 
patients were receiving warfarin in both cohorts (from 2% to 3.6% and from 1.3% to 3.3% 
for SDD and ON cases respectively), whereas the use of glycoprotein IIb/IIIa inhibitor 
sharply decreased, from 13.7% to 2.4% and from 28.4% to 7.1% for SDD and ON admitted 










(Supplementary Table 4) and when complicated ON cases were included (Supplementary 
Table 6). 
Independent factors associated with SDD 
Table 3 illustrate the independent predictors of SDD within the overall LMS cohort. 
Older patients were significantly less likely to be discharged (OR=0.99 per one year of age, 
95% CI 0.98-0.99), as were females (OR=0.85, 95% CI 0.74-0.98). Overall, LMS patients 
receiving glycoprotein IIb/IIIa inhibitor had significantly lower rates of SDD (OR=0.24, 95% 
CI 0.19-0.31), as in those in whom a penetration catheter was used (OR=0.23, 95% CI 0.12-
0.45). Renal disease, use of rotational atherectomy and prior peripheral vascular disease were 
also independently associated with ON, with OR=0.37 (95% CI 0.24 to 0.57), OR=0.51 (95% 
CI 0.40 to 0.66), and (OR=0.68, 95% CI 0.54-0.86) for SDD, respectively. Transradial PCI 
had the largest independent association with SDD, with OR=1.76 (95% CI 1.55 to 2.00), 
followed by offsite surgical cover, with OR=1.31 (95% CI 1.11 to 1.54). Finally, SDD 
frequency has increased significantly over time, with OR=1.09 (95% CI 1.06 to 1.12), after 
case-mix adjustment.  
Results of the independent associations with SDD for the unprotected LMS are 
displayed in Supplementary Table 7. Similar to the overall LMS cohort, older patients that 
underwent unprotected LMS PCI were less likely to be SDD, with OR=0.99 per one year of 
age (95% CI 0.98-0.99). Glycoprotein IIb/IIIa inhibitors and use of penetration catheters were 
the largest independent associations with ON, with OR=0.25 (95% CI 0.19-0.34) and 
OR=0.25 (95% CI 0.10-0.62) for SDD respectively. As for overall LMS, renal disease, use of 
rotational atherectomy and prior peripheral vascular disease were also independently 
associated to ON stay within the unprotected LMS cases. SDD was more common in those 
patients in whom PCI was performed transradially PCI, OR=1.80 (95% CI 1.51-2.14). SDD 
practice for the unprotected LMS also increased over calendar time, after adjustment for case-
mix (OR=1.10, 95% CI 1.05-1.14). 
Supplementary Table 8 displays the results of this analysis when including the 
complicated ON cases, where no meaningful differences were observed compared to the 
main analysis. Supplementary Table 2 displays in detail the types of complications and the 











Within the overall LMS cohort, mortality rates at 30 days post procedure were lower 
in the SDD cohort compared to uncomplicated ON cases, for all study years except 2008, and 
overall increased over time from 0% in 2007 to 0.7% in 2014 (Table 2). Supplementary 
Figure 2 shows a Kaplan Meier graph of the the day of death following the procedure for 
SDD and ON. Out of nine 30-day mortality cases that were SDD, the time of death recorded 
was after three days of the procedure for eight patients and at the first day following the 
procedure for one patient. A slow increase was also observed in 30-day mortality for the 
uncomplicated ON cases, from 0.9% in 2007 to 1.1% in 2014.  
Figure 5 illustrates temporal changes of the observed 30-day mortality of the SDD, 
the uncomplicated ON stay and all the cases combined, as well as the expected 30-day 
mortality calculated via the BCIS risk prediction model, for the overall LMS cohort. The 
observed increase of the 30-day mortality for the SDD was in line with expected mortality, 
similar to that observed in the ON cases. The large variation in the observed 30-day mortality 
rate is due to the low numbers of deaths. Similar trends were found in the unprotected LMS 
and overall LMS cohort including the complicated ON cohorts, compared to the overall 
LMS, with increases in the observed 30-day mortality rates which were in line with what was 
predicted from the BCIS model (Supplementary Figures 3 and 4).  
SDD was not independently associated with 30-day mortality for the overall LMS 
cohort, after a case-mix adjustment, with OR=0.72 (95% CI 0.31-1.71, P=0.459) (Table 4). 
Results were similar for the unprotected LMS and the overall LMS including complicated 
ON cases, with OR=0.48 (95% CI 0.17-1.41, P=0.185) and OR=0.58 (95% CI 0.25-1.34, 
P=0.206), respectively (Supplementary Tables 9 and 10).  
Discussion 
This paper presents the first study to examine the adoption of SDD in patients that 
underwent elective left main PCI and its relationship to complexity from a healthcare system 
where SDD is currently the standard of care in elective PCI.[32] We show that the prevalence 
of SDD for the LMS PCI has increased from 20% to 39% over our study period, although ON 
monitoring still remains the most common model of treatment for elective LMS PCI cases. 
Our analysis suggests that LMS PCI SDD cases are increasingly complex, increasingly 
undertaken in older patients, who were increasingly comorbid and with increasingly complex 
disease patterns such those that underwent PCI with rotational atherectomy use or with multi-










cases, 30-day mortality rates were in line with those estimated by the national risk score 
prediction model suggesting that SDD is not inferior to ON stay in higher risk cases that 
underwent LMS PCI. Finally, our analysis suggests significant regional heterogeneity of 
SDD adoption for LMS-PCI, which strengthens the need for national guidelines.  
Previous studies examining the safety of SDD after PCI have excluded (unprotected) 
LMS cases or have actively included them in the criteria for hospital admission.[5, 25-30] In 
studies in which LMS PCI was not a formal exclusion criterion, only small numbers of LMS 
PCI as SDD were undertaken,[2-4, 9, 12, 32, 41] which makes studying outcomes in this 
cohort of patients challenging. In the present analysis we observed a 2-fold increase in the 
adoption of SDD for elective LMS PCI and at the same time we observed increasingly 
comorbid patients treated as SDD, characterised by the greater prevalence of poor left 
ventricular function, valvular heart disease and comorbidities, such as diabetes, peripheral 
vascular disease, previous stroke, hypertension and renal dysfunction. The complexity cases 
also increased over time in the SDD group, i.e. use of rotational atherectomy or penetration 
catheters and multiple attempted vessels, suggesting that operators feel more comfortable of 
discharging cases of higher risk on the same day. Our data demonstrate that factors such as 
old age, female gender, peripheral vascular disease, renal impairment, use of glycoprotein 
IIb/IIIa inhibitor, rotational atherectomy, penetration catheters, and multivessel PCI are 
independently associated with ON observation. Previous studies have shown an independent 
association of many of these clinical and procedural features, in addition to LMS, with death 
and major adverse cardiac events, and contemporary PCI risk scores include them as risk 
factors.[35, 42-45]  
Our study results sh w that the transradial access site was increasingly used for LMS 
SDD PCI, and was the strongest independent predictor of SDD, after adjustment of patient 
case-mix. This is consistent with our recent study that examined access site practice for LMS 
PCI which showed that transradial PCI was associated with shorter length of stay and reduced 
in-hospital complications.[23]  
Patients with LMS disease are at higher risk for adverse clinical outcomes compared 
with patients undergoing PCI to other areas of the coronary circulation because anticipation 
of serious complications is high and admission to ON observation is commonly practised. 
The EXCEL randomised controlled trial reported 4.9% major adverse cardiac or 










days.[46] A similar RCT focusing on unprotected LMS, reported 0.02% MACCE events at 
30 days, including death, non-procedural MI, repeat revascularisation and stroke.[47] To 
examine the safety of SDD in LMS diseased patients after PCI, we compared the observed 
30-day mortality for both SDD and ON stay with predicted values of 30-day mortality, which 
were calculated from the BCIS mortality risk model -a risk adjustment model used for 
national public reporting of PCI outcomes. With this method we added an analysis were 
direct comparison between SDD and ON was avoided, as higher risk cases, will always be 
more likely to involve ON stay, and a direct comparison between SDD and ON would 
therefore tend to favour outcomes associated with SDD. In addition, we have excluded cases 
with peri- or early post-procedural complications, since these cases are, by default, admitted 
to ON observation, and early complications are highly associated with post-discharge major 
adverse events[48-50]. Our data show that the observed 30-day mortality rates for SDD were 
in line with those predicted from the BCIS model, even though the risk profile of the SDD 
cases after elective LMS PCI has increased over time. These results show no evidence that 
SDD after LMS PCI is not safe or feasible for patients selected by the usual criteria. In 
addition, our data may suggest that even if SDD patients were admitted for overnight 
observation, this would not prevent the mortality outcome. Most of patients’ mortality was 
recorded at 3 days following PCI, apart from one case were mortality was recorded at the first 
day following PCI and there is uncertainty of whether overnight stay would prevent that 
event due to lack of data regarding the exact timing of death (i.e. early in the morning or late 
at night).  
A previously published study examining the variation of SDD practice following 
elective PCI among different healthcare systems and practitioners, showed that only 14% of 
cardiologists practiced SDD in the US, 32% in Canada and 57% in the UK. At that study, 2% 
of the US cardiologists and 11% of the non-US reported SDD for LMS PCI. However, 59% 
of all the practitioners included in the study were unaware of any official guidelines for SDD 
after elective PCI in general and, therefore, after elective LMS PCI in particular.[51] In 2009, 
SCAI published a document defining the appropriate length of stay after elective PCI stating 
that LMS diseased cases should be always admitted for ON observation.[31] However, 
elective PCI has evolved to a safer procedure with less adverse outcomes driven by 
advancements in technology, medication and access site changes,[52] and more recent 
guidelines about the length of stay or about LMS PCI provide no information about the 










uncertainty at the operator level which may explain the significant heterogeneity in adoption 
of LMS PCI SDD that we have observed. More detailed guidelines, informed by an evolving 
evidence basis, such as data presented in this analysis, are required, and are of even higher 
significance during the current era of the Covid-19 pandemic as SDD is equivalent to 
shortened length of stay in the hospital which subsequently provides: (i) less exposure of 
patients to the virus, and (ii) increased bed availability for the increased demand in the 
hospitals due to Covid-19. 
The present study has several limitations. First, this is an observational study and 
patients were selected for SDD or ON stay based on operator’s discretion. Our data do not 
provide insight on whether the decision for SDD was taken before the PCI procedure was 
undertaken (intention to treat) or if the operator’s decision for SDD was altered due to peri-
procedural complexity or emergence of complications during the observational period. 
Second, the present analysis also lacks information about the length of the post-PCI 
observational period, the time of day that the procedure was undertaken, patient preference, 
family preference, patient circumstance (living distance from the hospital and presence of a 
companion in case of complications), procedural concerns or other factors that are likely to 
inform a clinicians’ decision for SDD. Similarly, our dataset does not include information 
about radial lounge monitoring, which has been found to be associated with increase in SDD, 
although no study has examined their association specifically for LMS PCI.[53, 54] In 
addition we are uncertain how operators choose which patients are SDD or are kept in for ON 
monitoring, how much of it relates to lesion / procedural complexity and how much is 
informed by local practices / guidelines. Third, our dataset only captures 30-day mortality 
outcomes and lacks information on post-discharge complications, such as MI, stroke, target 
vessel revascularization, or unplanned readmissions which limits the safety endpoints we are 
able to study. Nevertheless, significant major complications post discharge in the SDD cohort 
would have been manifest with an increased mortality risk at 30-days that we have not 
observed. Furthermore, ON monitoring would only capture complications sustained in the 
first 24 hours. Fourth, the limited number of deaths after SDD LMS-PCI did not allow us to 
examine which SDD patients’ characteristics are associated with higher mortality risk and 
perhaps distinguish those patients for whom SDD is safe and feasible after elective LMS PCI. 
Finally, our analysis only includes data from 2007 to 2014 which raises questions about more 











SDD following elective LMS PCI has become increasingly adopted in England and 
Wales, with increasingly complex cases undertaken over time, in elderly patients with more 
complex disease requiring rotational atherectomy, and with a greater prevalence of 
comorbidities, such as diabetes, previous stroke and peripheral vascular disease. Our analysis, 
found no evidence that SDD for LMS PCI is not safe in terms of 30-day mortality, and may 
help inform guidelines in this complex group of patients. 
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Table 1: Pre-procedural characteristics of the overall Left Main cases over time;  
p-value(p) tests the difference of the characteristic’s distributional change over time between SDD and ON 
  
2007 2008 2009 2010 2011 2012 2013 2014 p 
Size, n SDD 112 194 252 210 246 300 400 305 
 
 
uncON 451 515 531 520 582 611 762 461 
 Age in years, 
Mean (SD) 
SDD 66.0 65.8 66.6 67.0 67.6 68.7 67.8 68.7 0.2 
  
(9.9) (9.9) (10.5) (9.6) (9.5) (10.1) (9.9) (10.0) 
 
 
uncON 67.4 68.5 69.7 68.9 69.5 70.3 69.2 69.8 
 
  
(10.2) (10.6) (10.9) (10.7) (10.0) (10.6) (10.5) (10.3) 
 Gender 
         
0.02 
Male SDD 72.3 76.3 74.6 81.9 83.3 80.3 84.0 79.3 
 
 
uncON 80.0 79.0 77.0 73.8 76.8 76.4 79.4 78.7 
 Female SDD 27.7 23.7 25.4 18.1 16.7 19.7 16.0 20.7  
 uncON 20.0 21.0 23.0 26.2 23.2 23.6 20.6 21.3  
Ethnicity 
         
0.13 
Caucasian SDD 82.6 77.7 83.9 86.7 85.9 87.7 84.3 83.6 
 
 
uncON 87.7 82.7 89.3 89.9 89.6 86.5 84.8 85.1 
 Other SDD 17.4 22.3 16.1 13.3 14.1 12.3 15.7 16.4 
  uncON 17.4 17.3 10.7 10.1 10.4 13.5 15.2 14.9  
Medical history 
          
Previous MI SDD 46.1 42.3 34.5 33.7 46.6 41.7 39.1 46.0 0.4 
 
uncON 46.5 45.8 43.9 41.8 44.6 41.7 47.9 45.0 
 Previous CABG SDD 58.9 47.5 41.0 40.6 42.8 44.6 51.0 47.7 0.14 
 uncON 60.2 51.7 51.3 49.9 46.3 39.5 57.0 50.4  
Previous PCI SDD 39.4 31.6 33.7 38.5 32.2 33.1 41.9 42.5 0.63 
 
uncON 30.0 32.5 32.4 36.0 35.9 34.0 42.0 39.8 
 Hypercholesterol SDD 66.7 63.7 68.5 70.5 69.1 61.3 63.6 66.1 0.13 
 










Hypertension SDD 52.3 54.9 63.3 72.9 68.3 66.3 66.4 66.8 0.19 
 
uncON 52.7 60.9 67.9 67.1 68.8 73.7 69.5 71.4 
 Peripheral 
vascular disease 
SDD 2.7 4.1 5.2 6.2 7.8 5.7 7.5 5.0 0.67 
 
uncON 8.0 6.9 10.4 9.2 9.2 10.1 9.1 11.0 
 Q wave on ECG SDD 13.8 8.4 7.2 12.4 8.6 11.7 9.7 8.2 0.02 
 
uncON 17.3 18.5 14.0 15.7 9.8 9.9 11.3 8.3 
 Previous Stroke SDD 2.7 2.6 4.4 4.3 9.5 5.0 5.4 5.6 0.15 
 
uncON 4.1 5.4 6.8 4.8 5.9 5.0 4.0 6.6 
 Diabetes SDD 21.0 22.2 22.6 23.6 25.1 23.4 28.0 28.0 0.62 
 
uncON 21.3 29.1 25.9 21.3 27.4 24.4 29.5 30.8 
 Renal disease 
         
0.89 
No renal SDD 98.2 98.5 98.8 99.0 99.6 99.0 98.7 97.7 
 
 
uncON 98.0 94.9 95.4 96.1 96.3 96.1 95.9 95.6 
 High creatinine 
(>200 μmol/l – no 
dialysis) 
SDD 1.8 1.0 0.8 0.5 0.4 0.7 0.8 1.6 
  uncON 1.8 4.1 3.6 2.7 2.6 2.5 2.5 2.6  
Dialysis SDD 0.0 0.5 0.4 0.5 0.0 0.3 0.5 0.7 
 
 
uncON 0.2 1.0 1.0 1.2 1.0 1.3 1.6 1.7 
 Smoking 
         
0.64 
Ex-smoker SDD 64.7 57.0 50.9 53.5 53.7 49.8 53.1 53.6 
 
 
uncON 59.8 56.9 56.9 54.9 53.0 56.2 49.9 51.6 
 Current smoker SDD 9.4 8.7 8.5 9.6 10.4 10.8 9.5 8.2 
  uncON 8.7 8.0 9.1 7.6 8.9 6.5 8.2 8.5  
Never smoked SDD 25.9 34.3 40.6 36.9 35.9 39.4 37.4 38.2 
 
 
uncON 31.5 35.1 33.9 37.5 38.1 37.2 41.9 39.9 
 LVEF 
         
0.38 











uncON 72.0 66.2 65.3 68.6 72.6 68.7 70.6 76.2 
 Moderate  
(LVEF 30-50%) 
SDD 29.3 27.9 18.8 15.1 22.2 21.4 21.5 22.0 
  uncON 21.3 22.9 27.6 24 21.1 25.1 23.3 17.9  
Poor  
(LVEF <30%) 
SDD 2.4 4.5 4.7 4.1 3.4 6.0 4.4 4.9 
 
 
uncON 6.6 10.9 7.1 7.4 6.2 6.3 6.1 6.0 
 Multi-vessel 
disease 
SDD 34.9 39.3 44 52.7 55.5 55.9 51.0 51.7 0.03 
 
uncON 55.0 57.7 56.6 54.6 54.5 62.6 55.3 61.5 
 Valvular heart 
disease 
SDD 0.9 1.0 1.6 2.4 3.3 2.7 2.3 5.3 0.69 
 
uncON 1.1 1.6 3.2 4.4 4.4 5.6 4.6 5.7 
 Severe LMS 
stenosis pre-PCI 
SDD 30.5 30.1 37.0 41.6 48.5 46.5 40.9 48.1 <0.001 
 uncON 54.4 51.7 59.4 57.9 58.3 59.9 43.8 52.0  
*CABG=Coronary Artery Bypass Graft; ECG=Electrocardiogram; LVEF=Left ventricular ejection fraction; LMS=Left Main Stem; MI=Myocardial infarction; PCI=Percutaneous 




















Table 2: Procedural characteristics of the overall Left Main cases over time;  
p-value(p) tests the difference of the characteristic’s distributional change over time between SDD and ON 
  
2007 2008 2009 2010 2011 2012 2013 2014 p 
Medication received           
Warfarin  SDD 2.0 0.5 0.8 1.5 0.9 1.4 2.8 3.6 0.21 
 
uncON 1.3 1.7 2.4 1.4 1.8 2.2 2.6 3.3 
 Bivalirudin  SDD 0.0 0.0 0.0 0.0 0.9 0.4 0.3 0.0 0.87 
 
uncON 2.1 0.0 0.0 0.2 1.4 1.7 1.8 0.5 
 Clopidogrel SDD 100.0 100.0 100.0 100.0 100.0 95.7 95.1 92.9 0.4 
 
uncON 99.7 100.0 99.5 99.3 98.5 94.7 92.9 90.0 
 GP IIb/IIIa inhibitor SDD 13.7 9.5 7.1 4.5 2.2 3.8 2.0 2.4 0.33 
 
uncON 28.4 25.7 21.6 15.2 12.1 13.5 8.1 7.1 
 Offsite surgical 
cover 
SDD 25.3 32.5 42.1 38.4 41.2 46.2 33.5 33.7 0.01 
 
uncON 14.7 24.4 24.8 33.8 31.9 31.9 26.4 33.0 
 Ad hoc PCI SDD 15.8 18.6 17.5 14.5 16.0 22.3 23.4 26.2 0.35 
 
uncON 15.5 20.8 23.1 23.5 28.2 24.4 27.4 23.7 
 Multi-vessel 
attempted  
SDD 38.4 47.4 66.7 71.9 68.7 68.7 57.8 61.6 <0.001 
 
uncON 61.0 64.3 62.9 64.2 64.9 70.0 51.6 62.5 
 Stents use           
No stents SDD 27.4 22.9 18.0 16.6 13.4 11.7 13.6 6.5 <0.001 
 
uncON 7.1 5.7 5.0 6.3 8.1 5.4 6.3 4.7 
 BMS only SDD 24.2 18.4 8.3 3.6 7.1 4.2 4.3 2.1 
 
 
uncON 20.8 17.2 17.7 11.3 10.1 8.4 3.1 2.7 
 DES only SDD 41.1 50.8 66.7 76.2 75.2 77.4 77.9 90.0  
 uncON 60.6 67.1 70.1 77.3 77.9 82.8 86.0 88.9  
Both  SDD 7.4 7.8 7.0 3.6 4.2 6.7 4.3 1.4 
 
 
uncON 11.5 9.9 7.2 5.1 3.9 3.4 4.6 3.8 









mm, Mean (SD) 
  
(0.6) (0.6) (0.6) (0.6) (0.6) (0.7) (0.7) (0.6) 
 
 
uncON 3.7 3.8 3.9 4.0 3.9 3.9 3.8 3.9 
 
  
(0.6) (0.6) (0.7) (0.7) (0.6) (0.6) (0.7) (0.7) 
 Longest stent in 
mm, Mean (SD) 
SDD 20.5 26.9 29.1 28.4 25.8 28 28.1 30.2 0.02 
  
(13.1) (16.0) (19.4) (19.2) (18.0) (17.0) (18.9) (19.5) 
 
 
uncON 22.2 23.8 23.3 24.8 27.2 28.4 28.6 29.3 
 
  
(11.2) (13.4) (14.4) (15.7) (18.6) (18.2) (18.6) (17.9) 
 Rotational 
atherectomy  
SDD 1.1 1.7 4.2 4.4 3.5 6.6 6.8 6.4 0.07 
 
uncON 7.6 9.1 9.2 9.8 12.8 12.1 10.8 13.8 
 Intravascular 
imaging  
SDD 28.9 36.9 41.1 43.1 40.7 38.6 34.6 35.9 <0.001 
 
uncON 22.6 23.6 29.5 37.8 40.9 42.7 34.3 37 
 Penetration catheter SDD 0.0 0.0 0.0 0.0 0.4 0.3 1.0 1.4 0.96 
 
uncON 0.0 0.0 0.2 0.2 1.7 1.6 4.3 5.7 
 Access site           
Femoral only SDD 74.1 61.6 59.0 49.0 40.1 36.6 35.5 38.4 0.49 
 
uncON 81.8 78.8 71.9 65.0 60.0 56.1 50.7 45.3 
 Radial only SDD 24.1 38.4 40.2 47.6 57.4 60.3 61.7 58.3 
 
 
uncON 17.5 20.4 26.7 32.3 36.2 41.3 45.1 51 
 Multiple/ Other SDD 1.9 0.0 0.8 3.4 2.5 3.1 2.8 3.3 
 
 
uncON 0.7 0.8 1.3 2.7 3.8 2.6 4.2 3.7 
 Mortality 30-day SDD 0.0 1.5 0.4 0.0 0.4 0.3 0.2 0.7 0.52 
 
uncON 0.9 0.6 0.8 0.0 0.7 0.7 0.7 1.1 
 *BMS=Bare mare stent; DES=Drug-eluting stent; GP=Glycoprotein; LMS=Left Main Stem; PCI=Percutaneous Coronary Intervention; SD=Standard Deviation; SHA=Strategic 










Table 3: Multivariable logistic regression (with adjusted ORs) on the overall Left Main SDD 
cases. An OR<1 implies decreased odds of SDD 
 
OR for SDD 
vs uncON  
[95% CI] P>t 
Age per year 0.99 [0.98-0.99] <0.001 
Female 0.85 [0.74-0.98] 0.030 
Caucasian 0.82 [0.68-1.00] 0.05 
Medical History    
Previous MI 0.93 [0.81-1.07] 0.306 
Previous CABG 0.97 [0.83-1.12] 0.669 
Previous PCI 1.00 [0.88-1.13] 0.949 
High Cholesterol 0.95 [0.83-1.08] 0.427 
Hypertension 0.94 [0.83-1.07] 0.392 
Peripheral Vascular 
Disease 
0.68 [0.54-0.86] 0.002 
Q Wave on ECG 0.86 [0.69-1.06] 0.154 
Previous Stroke 1.18 [0.91-1.54] 0.220 
Diabetes 0.96 [0.84-1.11] 0.596 
Renal Disease 0.37 [0.24-0.57] <0.001 
Smoking    
Never Ref.   
Ex-smoker 1.05 [0.91-1.22] 0.482 
Current smoker 1.14 [0.91-1.43] 0.260 
LVEF    
Good Ref.   
Moderate  
(LVEF 30-50%) 
0.95 [0.80-1.13] 0.562 
Poor  
(LVEF<30%) 
0.85 [0.62-1.15] 0.290 
MVL disease 1.03 [0.89-1.20] 0.684 
Valvular Heart 
Disease 
0.78 [0.56-1.09] 0.149 
Severe LMS 
stenosis pre-PCI 
0.73 [0.63-0.84] <0.001 
Medication received    
Warfarin 0.86 [0.54-1.36] 0.515 
Bivalirudin 0.43 [0.14-1.31] 0.138 
Clopidogrel 1.43 [0.99-2.07] 0.056 
GP inhibitor 0.24 [0.19-0.31] <0.001 
Offsite surgical 
cover 
1.31 [1.11-1.54] 0.001 
Ad hoc PCI 0.76 [0.65-0.89] <0.001 
MVL attempted 1.10 [0.95-1.26] 0.192 
Stent use    
No stent Ref.   
BMS only 0.45 [0.33-0.60] <0.001 










Both 0.43 [0.31-0.60] <0.001 
Largest stent (mm) 0.80 [0.71-0.90] <0.001 
Longest stent (mm) 1.00 [0.99-1.00] 0.845 
Rotational 
atherectomy 
0.51 [0.40-0.66] <0.001 
Intravascular 
imaging 
0.97 [0.85-1.12] 0.765 
Penetration catheter 0.23 [0.12-0.45] <0.001 
Access site    
Femoral Ref.   
Radial 1.76 [1.55-2.00] <0.001 
Multiple / Other 1.00 [0.69-1.46] 0.984 
Year 1.09 [1.06-1.12] <0.001 
SHA    
London Ref.   
North East 1.25 [0.92-1.68] 0.148 
North West 1.67 [1.27-2.18] <0.001 
Yorkshire and the 
Humber 
0.50 [0.37-0.68] <0.001 
East Midlands 1.42 [1.11-1.81] 0.005 
West Midlands 0.86 [0.65-1.13] 0.274 
East of England 0.97 [0.75-1.27] 0.839 
South East Coast 1.02 [0.78-1.33] 0.891 
South Central 1.17 [0.89-1.54] 0.246 
South West 1.64 [1.26-2.13] <0.001 
Wales 2.43 [1.78-3.31] <0.001 
*BMS=Bare mare stent; CABG=Coronary Artery Bypass Graft; CI=Confidence Interval; DES=Drug-eluting 
stent; ECG=Electrocardiogram; GP=Glycoprotein; LVEF=Left ventricular ejection fraction; LMS=Left Main 
Stem; MI=Myocardial infarction; MVL=Multivessel; ON=Overnight stay; OR=Odds Ratio; PCI=Percutaneous 






















Table 4: Multivariable logistic regression (with adjusted ORs) on 30-days mortality for the overall 
Left Main cases.  
 
OR [95% CI] P>t 
SDD 0.70 [0.30-1.65] 0.417 
Age per year 1.01 [0.98-1.05] 0.456 
Female 0.70 [0.28-1.76] 0.451 
Caucasian 0.54 [0.18-1.57] 0.257 
Medical History    
Previous MI 1.74 [0.79-3.86] 0.170 
Previous CABG 0.20 [0.08-0.48] <0.001 
Previous PCI 0.73 [0.34-1.56] 0.416 
High Cholesterol 3.10 [1.12-8.56] 0.029 
Hypertension 1.15 [0.50-2.68] 0.741 
Peripheral Vascular 
Disease 
0.82 [0.26-2.61] 0.739 
Q Wave on ECG 1.02 [0.36-2.86] 0.975 
Previous Stroke 1.57 [0.42-5.87] 0.501 
Diabetes 1.72 [0.82-3.58] 0.150 
Renal Disease 2.33 [0.71-7.69] 0.165 
Smoking    
Never Ref.  
 Ex-smoker 1.18 [0.53-2.63] 0.687 
Current smoker 1.16 [0.32-4.19] 0.825 
LVEF    
Good Ref.  
 Moderate  
(LVEF 30-50%) 
1.50 [0.60-3.74] 0.380 
Poor  
(LVEF<30%) 
2.62 [0.80-8.51] 0.109 
MVL 4.13 [1.53-11.15] 0.005 
Severe LMS 
stenosis pre-PCI 
1.14 [0.52-2.48] 0.742 
Medication received    
Warfarin 1.77 [0.20-15.50] 0.604 
Bivalirudin 14.29 [2.54-80.48] 0.003 
GP inhibitor 1.60 [0.63-4.07] 0.326 
Offsite surgical 
cover 
1.28 [0.54-3.02] 0.575 
Ad hoc PCI 0.48 [0.18-1.33] 0.158 
MVL attempted 0.69 [0.29-1.64] 0.399 
Stent use    
No stent Ref.   
BMS only 0.93 [0.12-7.44] 0.948 
DES only 1.30 [0.28-6.09] 0.736 
Both 3.98 [0.70-22.64] 0.120 
Largest stent (mm) 0.48 [0.25-0.91] 0.026 












0.94 [0.29-3.05] 0.912 
Intravascular 
imaging 
1.22 [0.56-2.69] 0.619 
Penetration catheter 1.10 [0.10-11.46] 0.937 
Access site    
Femoral Ref.   
Radial 0.82 [0.6-1.84] 0.631 
Multiple / Other 0.40 [0.04-4.28] 0.449 
Year 1.07 [0.90-1.27] 0.448 
SHA    
London Ref.   
North East 2.27 [0.21-7.47] 0.792 
North West 1.44 [0.31-6.70] 0.638 
Yorkshire and the 
Humber 
0.19 [0.02-1.82] 0.149 
East Midlands 1.54 [0.42-5.61] 0.512 
West Midlands 0.50 [0.09-2.75] 0.426 
East of England 1.32 [0.35-4.98] 0.684 
South East Coast 1.00 - - 
South Central 1.43 [0.36-5.71] 0.615 
South West 0.42 [0.07-2.56] 0.351 
Wales 2.79 [0.83-9.42] 0.098 
*Clopidogrel use and Valvular heart disease were excluded from the analysis because of perfect prediction due 
to the low counts of mortality 
**BMS=Bare mare stent; CABG=Coronary Artery Bypass Graft; CI=Confidence Interval; DES=Drug-eluting 
stent; ECG=Electrocardiogram; GP=Glycoprotein; LVEF=Left ventricular ejection fraction; LMS=Left Main 
Stem; MI=Myocardial infarction; MVL=Multivessel; ON=Overnight stay; OR=Odds Ratio; PCI=Percutaneous 

























Figure 2: Percentage of Protected, unprotected, and Overall Left Main cases observed within the 
elective PCI cohort 
 
*The cumulative prevalence of protected and unprotected Left Main represents the Overall prevalence of Left Main cases within the elective 
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Figure 4: Spatial Maps of prevalence of SDD in the overall Left Main cohort over time in England 
and Wales 
 
*The more red coloured a region the higher SDD practice 




















































 In a national analysis of 6452 elective procedures undertaken for left main 
stem disease in United Kingdom, SDD practice was associated with similar 
risk of 30-day mortality compared to ON stay despite an increase complexity 
of procedure.  
 SDD did not appear inferior to ON stay even in highly complex left main stem 
PCI procedures.  
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